Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax (2014 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Long-Term Deferred Tax for 13 consecutive years, with $2.2 billion the latest figure, recorded in Q1 2026.

• Quarterly Long-Term Deferred Tax rose 24.29% year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 24.29% YoY) and the FY2025 annual result came in at $2.2 billion, up 21.79% from the prior year.
• Long-Term Deferred Tax steadied at $2.2 billion in Q1 2026 per TEVA's latest filing, from $2.2 billion in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for TEVA reached as high as $2.2 billion in Q4 2025 and fell as low as $637.0 million in Q1 2022.
• A 5-year average of $1.7 billion and a median of $1.8 billion in 2025 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax soared 148.55% — and 2025, when it retreated 21.06%.
• Year by year, Long-Term Deferred Tax stood at $1.5 billion in 2022, then climbed by 24.28% to $1.8 billion in 2023, then dropped by 0.72% to $1.8 billion in 2024, then rose by 21.79% to $2.2 billion in 2025, then declined by 0.05% to $2.2 billion in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $2.2 billion, $2.2 billion, and $1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.